Adenovirus-based therapies Gendicine, the first p53 gene therapy, is a recombinant human p53 adenovirus that was approved in 2003 by the China Food and Drug Administration (CFDA) for the treatment of HNSCC
Practitioners generally consider CJC-1295 when broader growth hormone optimization and body composition support are the primary objectives, while IGF-1 DES is more relevant when site-specific anabolic receptor-level activity is the goal
P-values indicate comparison between each treatment and control at the 10-week time point
Because your skin deserves honesty, purity, and care, we disclose every ingredient in our formulations, even at 0.01%
Those seeking general wellness support rather than treating specific acute injuries may find oral products adequate
A comprehensive association analysis confirms ZMIZ1 to be a susceptibility gene for vitiligo in Chinese population